Stefano Navarro: Partial GPVI Downregulation Shows Promise for Safer Antithrombotic Therapy
Stefano Navarro, Postdoctoral Researcher at Rudolf Virchow Center of University of Würzburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Signal Transduction and Targeted Therapy, adding:
“What if antiplatelet therapy does not always need to completely block a platelet receptor?
This is the idea we explored in our new article in Signal Transduction and Targeted Therapy.
Instead of fully blocking or downregulating the collagen/fibrin (fibrinogen) receptor Glycoprotein (GP) VI, we asked whether its surface expression could be ‘tuned down’ to an intermediate level.
By partially downregulating GPVI, we generated a low-density GPVI phenotype (GPVILO) in which the adhesive function of the receptor was largely preserved, while its intracellular signaling was selectively dampened.
This uncoupling of adhesion from signaling was sufficient to protect from thrombosis and thrombo-inflammation, while preserving hemostasis in our experimental models.
Many thanks to all co-authors and collaborators who contributed to this work, and especially to Bernhard Nieswandt for his guidance throughout the project.”
Title: Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection
Authors: Stefano Navarro, Sarah Beck, Sabrina I. Bonfiglio, Ernesto J. Cuenca-Zamora, Lukas J. Weiß, Marijke Kuijpers, Johan Heemskerk, David Stegner, Bernhard Nieswandt

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series